Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection
Introduction: Immunohistochemical staining for C4d in peritubular capillaries has been part of antibody-mediated rejection (AbMR) definition in the Banff Classification for Allograft Pathology since 2003. However, it has limited sensitivity and specificity, therefore the clinical significance of C4d...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-01-01
|
Series: | Kidney International Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468024918302031 |
id |
doaj-880cfddd007d4d088228bc0afb92e92a |
---|---|
record_format |
Article |
spelling |
doaj-880cfddd007d4d088228bc0afb92e92a2020-11-25T00:08:19ZengElsevierKidney International Reports2468-02492019-01-0141148158Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of RejectionKatherine M. Dominy0Michelle Willicombe1Tariq Al Johani2Hannah Beckwith3Dawn Goodall4Paul Brookes5H. Terence Cook6Tom Cairns7Adam McLean8Candice Roufosse9Centre for Inflammatory Diseases, Imperial College, London, UKCentre for Inflammatory Diseases, Imperial College, London, UKKing Saud University, Riyadh, Saudi ArabiaImperial College Healthcare NHS Trust, London, UKImperial College Healthcare NHS Trust, London, UKImperial College Healthcare NHS Trust, London, UKCentre for Inflammatory Diseases, Imperial College, London, UK; Imperial College Healthcare NHS Trust, London, UKImperial College Healthcare NHS Trust, London, UKImperial College Healthcare NHS Trust, London, UKCentre for Inflammatory Diseases, Imperial College, London, UK; Imperial College Healthcare NHS Trust, London, UK; Correspondence: Candice Roufosse, Imperial College, Hammersmith Campus, Commonwealth Building 9th Floor (Centre for Inflammatory Diseases), Du Cane Road, London, W12 0HS, UK.Introduction: Immunohistochemical staining for C4d in peritubular capillaries has been part of antibody-mediated rejection (AbMR) definition in the Banff Classification for Allograft Pathology since 2003. However, it has limited sensitivity and specificity, therefore the clinical significance of C4d-positive biopsies without evidence of rejection (C4d+ WER) is unknown. We investigated the transcript levels of genes associated with AbMR in C4d+ WER biopsies from both ABO-compatible and incompatible renal transplant patients. Methods: RNA was extracted from formalin-fixed paraffin-embedded renal transplant biopsies (n = 125) and gene expression analysis of 35 AbMR-associated transcripts carried out using the NanoString nCounter system. Results: AbMR-associated transcripts were significantly increased in samples with AbMR or suspicious AbMR. A subgroup of 17 of 35 transcripts that best distinguished AbMR from C4d-negative biopsies without evidence of rejection was used to study C4d+ WER samples. There was no differential expression between C4d-negative and C4d+ WER from both ABO-incompatible and -compatible transplants. The geometric mean of 17 differentially expressed genes was used to assign the C4d+ WER biopsies a high- or low-AbMR transcript score. Follow-up biopsies showed AbMR within 1 year of initial biopsy in 5 of 7 high-AbMR transcript patients but only 2 of 46 low-AbMR transcript patients. In multivariate logistic regression analysis, elevated transcript levels in a C4d+ WER biopsy were associated with increased odds for biopsy-proven AbMR on follow-up (P = 0.032, odds ratio 16.318), whereas factors including donor-specific antibody (DSA) status and time since transplantation were not. Conclusion: Gene expression analysis in C4d+ WER samples has the potential to identify patients at higher risk of developing AbMR. Keywords: antibody mediated rejection, C4d, kidney, molecular, transplant rejectionhttp://www.sciencedirect.com/science/article/pii/S2468024918302031 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Katherine M. Dominy Michelle Willicombe Tariq Al Johani Hannah Beckwith Dawn Goodall Paul Brookes H. Terence Cook Tom Cairns Adam McLean Candice Roufosse |
spellingShingle |
Katherine M. Dominy Michelle Willicombe Tariq Al Johani Hannah Beckwith Dawn Goodall Paul Brookes H. Terence Cook Tom Cairns Adam McLean Candice Roufosse Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection Kidney International Reports |
author_facet |
Katherine M. Dominy Michelle Willicombe Tariq Al Johani Hannah Beckwith Dawn Goodall Paul Brookes H. Terence Cook Tom Cairns Adam McLean Candice Roufosse |
author_sort |
Katherine M. Dominy |
title |
Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection |
title_short |
Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection |
title_full |
Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection |
title_fullStr |
Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection |
title_full_unstemmed |
Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection |
title_sort |
molecular assessment of c4d-positive renal transplant biopsies without evidence of rejection |
publisher |
Elsevier |
series |
Kidney International Reports |
issn |
2468-0249 |
publishDate |
2019-01-01 |
description |
Introduction: Immunohistochemical staining for C4d in peritubular capillaries has been part of antibody-mediated rejection (AbMR) definition in the Banff Classification for Allograft Pathology since 2003. However, it has limited sensitivity and specificity, therefore the clinical significance of C4d-positive biopsies without evidence of rejection (C4d+ WER) is unknown. We investigated the transcript levels of genes associated with AbMR in C4d+ WER biopsies from both ABO-compatible and incompatible renal transplant patients. Methods: RNA was extracted from formalin-fixed paraffin-embedded renal transplant biopsies (n = 125) and gene expression analysis of 35 AbMR-associated transcripts carried out using the NanoString nCounter system. Results: AbMR-associated transcripts were significantly increased in samples with AbMR or suspicious AbMR. A subgroup of 17 of 35 transcripts that best distinguished AbMR from C4d-negative biopsies without evidence of rejection was used to study C4d+ WER samples. There was no differential expression between C4d-negative and C4d+ WER from both ABO-incompatible and -compatible transplants. The geometric mean of 17 differentially expressed genes was used to assign the C4d+ WER biopsies a high- or low-AbMR transcript score. Follow-up biopsies showed AbMR within 1 year of initial biopsy in 5 of 7 high-AbMR transcript patients but only 2 of 46 low-AbMR transcript patients. In multivariate logistic regression analysis, elevated transcript levels in a C4d+ WER biopsy were associated with increased odds for biopsy-proven AbMR on follow-up (P = 0.032, odds ratio 16.318), whereas factors including donor-specific antibody (DSA) status and time since transplantation were not. Conclusion: Gene expression analysis in C4d+ WER samples has the potential to identify patients at higher risk of developing AbMR. Keywords: antibody mediated rejection, C4d, kidney, molecular, transplant rejection |
url |
http://www.sciencedirect.com/science/article/pii/S2468024918302031 |
work_keys_str_mv |
AT katherinemdominy molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection AT michellewillicombe molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection AT tariqaljohani molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection AT hannahbeckwith molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection AT dawngoodall molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection AT paulbrookes molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection AT hterencecook molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection AT tomcairns molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection AT adammclean molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection AT candiceroufosse molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection |
_version_ |
1725415807393988608 |